Is Enclomiphene Actually Dangerous?

The fear around enclomiphene almost always starts in the same place, which is a person reading about Clomid side effects and assuming enclomiphene is the same thing.

It is not the same thing, and understanding why requires starting one level up.

Your brain runs testosterone production through a feedback loop, something called the HPG axis, which is the chain of signals running from your hypothalamus down to your pituitary and then down to your testes. The hypothalamus releases a signal that tells the pituitary to release LH and FSH, and those hormones travel through the bloodstream and tell the testes to make testosterone. When testosterone rises high enough, the brain detects it, partially by converting some of it into estrogen, and that estrogen feeds back to the hypothalamus and pituitary to slow the signal down. The system is self-regulating. More testosterone means quieter signals from the brain.

Enclomiphene works by sitting in the estrogen receptors at the hypothalamus and pituitary and blocking that feedback signal, so the brain never gets the message to slow down, and it keeps signaling the testes to produce more testosterone. The whole cascade stays active. That is the mechanism.

Clomiphene, the drug sold as Clomid, contains enclomiphene but it also contains a second molecule called zuclomiphene, and zuclomiphene does something different. Where enclomiphene blocks estrogen receptors, zuclomiphene activates them, and because zuclomiphene clears the body extremely slowly it accumulates over time and drives estrogen effects at the same receptors enclomiphene is trying to block. Enclomiphene has a half-life of roughly 10 hours and clears quickly. Zuclomiphene lingers for days. Clomiphene is approximately 62% enclomiphene and 38% zuclomiphene, so when someone takes Clomid they are running two molecules with opposing actions simultaneously.

That distinction matters because the side effects people associate with Clomid, the mood instability, the visual disturbances, the decreased libido, trace back almost entirely to the zuclomiphene component and its estrogenic activity, not to enclomiphene.

The 2024 study out of Baylor put this directly to the test, comparing both compounds head to head in 66 men, and the numbers are clear. Men on clomiphene reported side effects at a rate of 47%. Men on enclomiphene reported side effects at a rate of 13.8%, a statistically significant difference with a p-value of 0.001. Mood changes occurred in 9.1% of the clomiphene group and 0% of the enclomiphene group. Decreased libido dropped from 33.3% in the clomiphene group down to 8.6% in the enclomiphene group.

The estradiol data is equally telling. Clomiphene raised estradiol. Enclomiphene decreased it. That directional difference is the zuclomiphene component showing its effects in the Clomid group, and its absence explaining the enclomiphene results.

A 2025 meta-analysis reviewed 10 randomized controlled trials covering 819 patients, and across all of that published data no severe adverse events were reported. The adverse event rate pooled at 21%, but severity was not the story. SERM therapy raised total testosterone by an average of 273.76 ng/dL compared to placebo, which is a clinically meaningful increase achieved without the severe risk profile people assume exists.

Earlier work from 2013 looked at 44 men taking 25 mg of enclomiphene over six weeks and found average testosterone levels reaching 604 ng/dL. The researchers also measured thyroid stimulating hormone, ACTH, cortisol, lipids, and bone markers across the treatment period and found no meaningful changes in any of them, meaning the drug's action stayed targeted to the HPG axis rather than disrupting other hormonal systems.

One 2014 trial ran 124 men through three months of enclomiphene and tracked both testosterone and sperm counts, which matters because testosterone replacement therapy typically suppresses sperm production by shutting down the same HPG signals that enclomiphene is trying to keep active. In that study testosterone rose from a mean of 217 ng/dL to 472 ng/dL on the 12.5 mg dose while mean sperm counts stayed at 176 million per milliliter, which is well within the normal range. The mechanism explains this outcome directly: enclomiphene keeps the upstream signals running, so the testes receive continuous stimulation for both testosterone and sperm production rather than having that signal bypassed.

There are real limitations worth naming. The longest published follow-up period in the literature is approximately six months, so the long-term safety picture beyond that window is genuinely unknown. The FDA rejected the branded version called Androxal, though the rejection was over study design concerns rather than a safety signal in the data itself. Because enclomiphene is currently available primarily through compounding pharmacies, product quality is variable in ways that pharmaceutical manufacturing is not, and that introduces a practical risk that has nothing to do with the molecule itself.

None of that uncertainty disappears by pointing to the short-term data. The honest read of the published evidence is that enclomiphene does not carry the risk profile of clomiphene, and the fear surrounding it largely belongs to a different compound, but it is still a pharmacologically active drug, it is still altering hormonal signaling, and baseline labs and follow-up labs are the minimum responsible approach.

The broader point is that enclomiphene and clomiphene are not interchangeable names for the same thing, and treating them as synonymous is what produces the distorted picture that circulates online. When you separate the molecule from the mixture it came from and look at what enclomiphene actually does on its own, the data tells a different story than the reputation suggests.

---

References

1. Saffati G, Kassab J, Orozco Rendon D, et al. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men. Translational Andrology and Urology. 2024;139:1979-1987. Finding: Side effects: clomiphene 47% vs enclomiphene 13.8% p=0.001. Mood changes: 9.1% vs 0% p=0.03. Decreased libido: 33.3% vs 8.6% p=0.001. Estradiol decreased with enclomiphene, increased with clomiphene p=0.001. Source
2. Hohl A, Chavez MP, Pasqualotto E, et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Archives of Endocrinology and Metabolism. 2025. Finding: 10 RCTs, 819 patients. SERM therapy increased total testosterone by 273.76 ng/dL vs placebo p<0.01. 21% experienced adverse events; none were severe. Source
3. Wiehle RD, Cunningham GR, Pitteloud N, et al. Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism. BJU International. 2013;1128:1188-1200. Finding: 44 men, 6 weeks. 25 mg enclomiphene averaged 604 ng/dL testosterone. No effects on TSH, ACTH, cortisol, lipids, or bone markers. Source
4. Wiehle R, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia. Fertility and Sterility. 2014;1023:720-727. Finding: 124 men, 3 months. Testosterone rose from 217 to 472 ng/dL 12.5 mg. Sperm counts preserved mean 176 million/mL. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness